Faeth Therapeutics, Inc. (FTH) is a clinical-stage oncology biotechnology company — formerly Sensei Biotherapeutics — developing PIKTOR, a multi-node PI3K/AKT/mTOR inhibitor, for endometrial and breast cancer, along with the VISTA-targeting antibody Solnerstotug. As a stock with active sell-side coverage, it carries genuine analyst price targets, though the post-data volatility has left the field unusually wide.
Four recent targets could be attributed to named firms and dates: BTIG at $55 (November 9, 2026), Lucid Capital at $59 (November 9, 2026), H.C. Wainwright at $60 (November 9, 2026), and Guggenheim at $69 (revised from $70 on November 4, 2026). Their arithmetic mean of $60.75 rounds to the $61 central target used here. Broader data providers tracking roughly 15 to 17 analysts report a wider band of about $40 to $70, with most recent actions clustered in the mid-to-high $50s and $60s.
Views are almost uniformly bullish, but the reasoning differs. Bulls emphasize durable disease control and manageable toxicity; more cautious analysts flag that the headline response rate merely matches — rather than clearly beats — emerging antibody-drug conjugates (ADCs). That divergence explains the unusually wide range.
Shares last traded near $12.68, down roughly 42% in a single session after topline Phase 2 PIK-201 results in advanced PAM-pathway-altered endometrioid endometrial cancer. The stock fell as low as about $10.45 intraday, its weakest level since just before the reverse merger that created the current entity. The 52-week range spans $7.45 to $42.14, with a market capitalization of roughly $328 million.
From $12.68, reaching $61 implies upside of about 381% — a very large move. For a pre-revenue biotech, the realistic path is event-driven rather than gradual: successive positive readouts on PIKTOR's breast cancer program, successful regulatory engagement, and progress toward pivotal trials would each need to re-rate the shares meaningfully. No single quarter's fundamentals can bridge a gap this wide.
The Phase 2 PIK-201 trial reported a 33% confirmed objective response rate (ORR) in 36 efficacy-evaluable patients, an 83% disease control rate, and a preliminary median progression-free survival (PFS) of about 7.4 months — well above the roughly three-to-four-month benchmark of contemporary salvage chemotherapy. Several analysts called the selloff "overdone" or "disproportionate," arguing the market underweighted durability and tolerability.
Additional supports include a differentiated safety profile, a breast cancer readout (PIK-101) expected in 2027, anticipated Phase 3 regulatory guidance in early 2027, and roughly $186 million in cash as of the most recent quarter. A clinical-stage valuation reset after the selloff also gives analyst price targets significant headroom.
The principal obstacle is binary clinical risk: a disappointing PIK-101 breast cancer readout or unfavorable regulatory feedback would undermine the thesis that PIKTOR is differentiated. The 33% ORR, while within prior guidance, sits broadly in line with emerging ADCs rather than clearly above them, and six patients were excluded from the efficacy analysis.
As a pre-revenue company, FTH carries heavy losses — a quarterly net loss of roughly $16 million and trailing diluted EPS (earnings per share) near -$22.50 — and will likely need additional capital, risking dilution. Broader factors, including biotech risk appetite and interest rates, also influence how richly early-stage pipelines are valued.
The post-data plunge reset the chart. Intraday support emerged near $10.45, close to the stock's June low around $10; a decisive break below that zone would leave the 52-week low of $7.45 as the next reference. On the upside, the day's high near $16.64 and the prior close near $22 mark the first meaningful resistance levels. The long-term structure remains dominated by the $7.45–$42.14 range, and any sustainable move toward $61 would require a sequence of higher highs well beyond current technical resistance.
Analyst price targets typically reflect a roughly 12-month research horizon, and the targets reviewed here were issued or reaffirmed in late October and November 2026. Investors should watch for the PIK-101 breast cancer readout in 2027, early-2027 Phase 3 regulatory guidance, further details on PIK-201 durability, cash runway updates in quarterly results, and any analyst target revisions as the data set matures.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a volatile name like FTH, such signals can help traders spot changing trends more efficiently, discover new opportunities, and monitor existing positions without manually screening every chart. Traders seeking an additional, data-driven layer to their market outlook may find the signals a useful complement to fundamental research.
The $61 central target reflects a calculated average of recent, verifiable analyst targets, against a latest price near $12.68 — a required move of about 381%, which is very large. Support comes from encouraging Phase 2 efficacy, a manageable safety profile, and a clearly identifiable set of near-term catalysts, while the obstacles are equally clear: binary clinical outcomes, a response rate that does not yet clearly outpace competing ADCs, and ongoing financing needs. With analyst views spanning roughly $40 to $70, the dispersion itself signals real uncertainty about how far the pipeline thesis can run. Whether FTH approaches $61 will depend primarily on the next clinical readouts and regulatory milestones rather than on valuation alone.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, FTH has been loosely correlated with VSTM. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if FTH jumps, then VSTM could also see price increases.
| Ticker / NAME | Correlation To FTH | 1D Price Change % | ||
|---|---|---|---|---|
| FTH | 100% | +1.89% | ||
| VSTM - FTH | 47% Loosely correlated | +0.34% | ||
| ALZN - FTH | 40% Loosely correlated | -5.92% | ||
| MOLN - FTH | 39% Loosely correlated | +4.84% | ||
| ZURA - FTH | 37% Loosely correlated | +13.31% | ||
| INAB - FTH | 37% Loosely correlated | -4.27% | ||
More | ||||